CWA Asset Management Group LLC Sells 16,783 Shares of Pfizer Inc. (NYSE:PFE)

CWA Asset Management Group LLC trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 35.2% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 30,959 shares of the biopharmaceutical company’s stock after selling 16,783 shares during the period. CWA Asset Management Group LLC’s holdings in Pfizer were worth $821,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Pensionfund Sabic increased its position in Pfizer by 41.7% in the fourth quarter. Pensionfund Sabic now owns 85,000 shares of the biopharmaceutical company’s stock worth $2,255,000 after purchasing an additional 25,000 shares during the last quarter. Nordea Investment Management AB increased its holdings in shares of Pfizer by 36.1% in the 4th quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company’s stock worth $108,002,000 after buying an additional 1,080,822 shares during the last quarter. Central Pacific Bank Trust Division raised its position in shares of Pfizer by 95.1% during the 4th quarter. Central Pacific Bank Trust Division now owns 18,118 shares of the biopharmaceutical company’s stock valued at $481,000 after buying an additional 8,832 shares in the last quarter. Versant Capital Management Inc lifted its holdings in shares of Pfizer by 53.3% in the 4th quarter. Versant Capital Management Inc now owns 6,799 shares of the biopharmaceutical company’s stock valued at $180,000 after acquiring an additional 2,365 shares during the last quarter. Finally, Trust Co of the South grew its position in Pfizer by 6.1% in the fourth quarter. Trust Co of the South now owns 28,945 shares of the biopharmaceutical company’s stock worth $768,000 after acquiring an additional 1,667 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Scott Gottlieb bought 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. The trade was a 11.11 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on PFE. Guggenheim lowered their price objective on Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Bank of America reaffirmed a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Truist Financial dropped their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Finally, Wolfe Research initiated coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective for the company. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $32.15.

Pfizer Stock Up 0.9 %

NYSE:PFE opened at $27.12 on Wednesday. The company’s 50-day simple moving average is $26.27 and its 200-day simple moving average is $28.07. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The stock has a market capitalization of $153.69 billion, a P/E ratio of 36.65, a P/E/G ratio of 0.63 and a beta of 0.64.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. During the same period last year, the business posted ($0.17) earnings per share. The firm’s revenue was up 31.2% compared to the same quarter last year. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.34%. Pfizer’s dividend payout ratio is presently 232.43%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.